Literature DB >> 20151057

Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience.

Jon-David R Schwalm1, Mayraj Ahmad, James L Velianou, Dan Pericak, Madhu K Natarajan.   

Abstract

BACKGROUND: In randomized trials, paclitaxel-eluting stents (PES) are superior to bare metal stents (BMS) in reducing target lesion revascularization (TLR). However, recent reports suggest there may be an increase in late stent thrombosis with long-term follow-up in PES-treated patients.
METHODS: Prospectively collected data from a regional cardiac referral centre were analyzed to compare PES versus BMS in all consecutive patients undergoing percutaneous coronary intervention from April 2003 to March 2004. Outcomes included combined death, myocardial infarction and clinically driven TLR, as well as stent thrombosis at four years follow-up.
RESULTS: A total of 512 patients were treated with PES and 722 patients with BMS. At four years, there was 92% follow-up in both groups. The composite outcome of death, myocardial infarction and TLR was 13.9% in the PES group compared with 20% in the BMS group (P=0.01). This difference was primarily driven by the reduction in TLR in the PES cohort (3.9% versus 8%, P<0.01). The rate of definite stent thrombosis was 1.6% in the PES group compared with 0.4% in the BMS group (P=0.03).
CONCLUSION: While PES offers an absolute 4.1% reduction in clinically driven TLR at four years, there is an associated increased risk of stent thrombosis. Further long-term studies addressing clinical outcomes including stent thrombosis with PES versus BMS are required to clarify this risk/ benefit balance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151057      PMCID: PMC2851390          DOI: 10.1016/s0828-282x(10)70005-2

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  21 in total

1.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS).

Authors:  D Hasdai; S Behar; L Wallentin; N Danchin; A K Gitt; E Boersma; P M Fioretti; M L Simoons; A Battler
Journal:  Eur Heart J       Date:  2002-08       Impact factor: 29.983

2.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.

Authors:  Raúl Moreno; Cristina Fernández; Rosana Hernández; Fernando Alfonso; Dominick J Angiolillo; Manel Sabaté; Javier Escaned; Camino Bañuelos; Antonio Fernández-Ortiz; Carlos Macaya
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

3.  Long-term outcomes of patients receiving drug-eluting stents.

Authors:  Andrew C Philpott; Danielle A Southern; Fiona M Clement; P Diane Galbraith; Mouhieddin Traboulsi; Merril L Knudtson; William A Ghali
Journal:  CMAJ       Date:  2008-12-18       Impact factor: 8.262

Review 4.  What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Deepak L Bhatt
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

6.  Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE).

Authors:  Philippe Gabriel Steg; Robert J Goldberg; Joel M Gore; Keith A A Fox; Kim A Eagle; Marcus D Flather; Immad Sadiq; Rachel Kasper; Sophie K Rushton-Mellor; Frederick A Anderson
Journal:  Am J Cardiol       Date:  2002-08-15       Impact factor: 2.778

7.  One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.

Authors:  Eberhard Grube; Sigmund Silber; Karl Eugen Hauptmann; Ralf Mueller; Lutz Buellesfeld; Ulrich Gerckens; Mary E Russell
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

10.  Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.

Authors:  Antonio Colombo; Janusz Drzewiecki; Adrian Banning; Eberhard Grube; Karl Hauptmann; Sigmund Silber; Dariusz Dudek; Stephen Fort; Francois Schiele; Krysztof Zmudka; Giulio Guagliumi; Mary E Russell
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

View more
  2 in total

1.  Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): protocol for a pragmatic, cluster-randomized controlled trial.

Authors:  Noah M Ivers; Jon-David Schwalm; Jeremy M Grimshaw; Holly Witteman; Monica Taljaard; Merrick Zwarenstein; Madhu K Natarajan
Journal:  Implement Sci       Date:  2012-06-09       Impact factor: 7.327

2.  Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents.

Authors:  Jang-Won Son; Ung Kim; Jong-Seon Park; Young-Jo Kim; Jae-Sik Jang; Tae-Hyun Yang; Dong-Soo Kim; Dong-Kie Kim; Sang-Hoon Seol; Doo-Il Kim; Chang-Wook Nam; Seung-Ho Hur; Kwon-Bae Kim
Journal:  Korean J Intern Med       Date:  2012-12-28       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.